Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22281268 | 0.94 | PDE2A (0.37) | BRD4CREBBPTRPV1MAPK1TAS1R3 | |
| SCHEMBL23343385 | 0.87 | BRD4 (0.39) | BRD4CREBBPTRPV1MAPK1TAS1R3 | |
| SCHEMBL22281266 | 0.86 | MAPK1 (0.35) | BRD4CREBBPTRPV1MAPK1PDE2A | |
| SCHEMBL22280905 | 0.86 | BRD4 (0.37) | BRD4CREBBPTRPV1MAPK1TAS1R3 | |
| SCHEMBL22281263 | 0.84 | P2RX7 (0.40) | BRD4CREBBPTRPV1MAPK1TAS1R3 | |
| SCHEMBL22281282 | 0.82 | P2RX7 (0.39) | BRD4CREBBPTRPV1MAPK1TAS1R3 | |
| SCHEMBL31171088 | 0.82 | P2RX7 (0.39) | BRD4CREBBPTRPV1MAPK1TAS1R3 | |
| SCHEMBL22280891 | 0.81 | MAPK1 (0.38) | BRD4CREBBPTRPV1MAPK1PDE2A | |
| SCHEMBL22281226 | 0.81 | PDE2A (0.37) | BRD4CREBBPTRPV1MAPK1TAS1R3 | |
| SCHEMBL24251393 | 0.81 | BRD4 (0.37) | BRD4CREBBPTRPV1MAPK1TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10934301-B2 | Pyrazolopyrimidine derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2021-03-02 | — | — | US | disclosed |
| US-20200239482-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239482-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES | P2RX5, RECQL, P2RX1 | BRD4 1501/4885CREBBP 4233/4885TRPV1 1628/4885 |
| US-10934301-B2 | Pyrazolopyrimidine derivatives | P2RX5, RECQL, P2RX1 | BRD4 1501/4885CREBBP 4233/4885TRPV1 1628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.